ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways
نویسندگان
چکیده
Authors' A Pediatrics Comprehen University o and 3Path Medicine a Biology Ins California Research, Laboratorie
منابع مشابه
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
The Ewing Sarcoma (EWS) family of tumors is one of the most common tumors diagnosed in children and adolescents and is characterized by a translocation involving the EWS gene. Despite advances in chemotherapy, the prognosis of metastatic EWS is poor with an overall survival of <30% after 5 years. EWS tumor cells express the receptor tyrosine kinases, platelet-derived growth factor receptor (PDG...
متن کاملمهار مسیرهای سیگنالی فاکتورهای رشد توسط داروی ایماتینیب مسیلات در سلولهای لایدیگ نرمال موشی
Background & Aims : Cancer cells proliferation may be mediated by abnormal phosphorylation of signaling pathways downstream of tyrosine kinase receptors such as Platelet derived growth factor receptor α (PDGFR-α) and β (PDGFR-β). We aimed to study the phosphorylation level of PDGFR-α and PDGFR-β and apoptosis in mouse normal leydig cells being exposed to Imatinib. Materials & Methods : The ...
متن کاملABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents.ABT-869, a novel ATP-competitive receptor tyrosine kinase inhibitor is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and ...
متن کاملPreclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 micromol/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition prof...
متن کاملImatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
PURPOSE AND EXPERIMENTAL DESIGN The stem cell factor/KIT receptor loop may represent a novel target for molecular-based therapies of Ewing tumor. We analyzed the in vitro impact of KIT blockade by imatinib in Ewing tumor cell lines. RESULTS KIT expression was detected in 4 of 4 Ewing tumor cell lines and in 49 of 110 patient samples (44.5%) by immunohistochemistry and/or Western blot analysis...
متن کامل